跳至主要内容
临床试验/NCT01050374
NCT01050374已完成不适用

Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study

DBL -Institute for Health Research and Development1 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
650
试验地点
1
主要终点
Efficacy of treatment

研究概览

简要总结

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
1 Year 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Those with an age of 1-15 years of age
  • Are infected with schistosomiasis and soil-transmitted helminthiasis
  • Whose parent consent and who are willing to participate

排除标准

  • Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis
  • Those with a history of any serious adverse drug reactions

研究组 & 干预措施

1

Placebo Comparator

albendazole + praziquantel

干预措施: albendazole + praziquantel (Drug)

2

Active Comparator

mebendazole + praziquantel

干预措施: mebendazole + praziquantel (Drug)

结局指标

主要结局

Efficacy of treatment

时间窗: 6 weeks

次要结局

  • Record of adverse reactions(6 weeks)

研究者

发起方
DBL -Institute for Health Research and Development
申办方类型
Other

研究点 (1)

Loading locations...

相似试验